DNA methylation biomarkers for predicting lymph node metastasis in colorectal cancer
-
Yu Sun [1] ; Deyang Kong [1] ; Qi Zhang [1] ; Renshen Xiang [1] ; Shuaibing Lu [1] ; Lin Feng [1] ; Haizeng Zhang [1]
-
[1] State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 27, Nº. 2, 2025, págs. 439-448
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Colorectal cancer is one of the most common cancers worldwide. Lymph node metastasis is an important marker of colorectal cancer progression and plays a key role in the evaluation of patient prognosis. Accurate preoperative assessment of lymph node metastasis is crucial for devising appropriate treatment plans. However, current clinical imaging methods have limitations in many aspects. Therefore, the discovery of a method for accurately predicting lymph node metastasis is crucial clinical decision-making. DNA methylation is a common epigenetic modification that can regulate gene expression, which also has an important impact on the development of colorectal cancer. It is considered to be a promising biomarker with good specificity and stability and has promising application in predicting lymph node metastasis in patients with colorectal cancer. This article reviews the characteristics and limitations of currently available methods for predicting lymph node metastasis in patients with colorectal cancer and discusses the role of DNA methylation as a biomarker.
